Antibiotic resistance market is expected to reach USD 17387.01 million at CAGR of 5.34% during the forecast period of 2020 to 2030
According to the latest research report, The Antibiotic Resistance Market size is estimated to reach USD 17387.01 million by 2030, growing at a compound annual growth rate of 5.34%. Antibiotics are growing more inadequate as antibiotic resistance increases around the world, resulting in illnesses that are more difficult to eradicate and deaths. New antibacterial agents are needed, for example, to address carbapenem-resistant gram-negative infectious diseases, which have been listed as a concern pathogen by the World Health Organization. The rising prevalence of antibiotic-resistant diseases, as well as the introduction of multidrug-resistant bacteria, are driving the market's expansion. These variables have had an influence on the development of the healthcare sector.
Antibiotic resistance happens naturally. However, the overuse of antibiotics in people will accelerate the spread of antimicrobial resistance in the environment. This is because bacteria develop resistance to the drugs that are intended to kill them over time. In addition, the introduction of multidrug-resistant bacteria and the increase in antibiotic-resistant illnesses will aid in the expansion of the antibiotic resistance market value. According to the World Health Organization, around 49,000 persons worldwide acquired multidrug-resistant tuberculosis in 2016, while drug resistance is affecting the battle against Hiv/ aids.
This report contains all the information on the global Antibiotic Resistance Market analysis and its strengths. In addition, the report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other essential factors. And a detailed analysis of the global Antibiotic Resistance Market forecast for 2025 is also included in the report.
Covid 19 Analysis
The COVID-19 problem has contributed to a better insight into the economic and health consequences of an unregulated epidemic over the world. Moreover, it emphasized the need for long-term financing to tackle these dangers, such as expenditures in research and development of antimicrobial medications and vaccines, while also demonstrating how quickly progress can be accomplished whenever there is sufficient political will and entrepreneurial spirit.
The Antibiotic Resistance Market growth is predicted to expand due to an increase in the number of illnesses that are resistant to antibiotics. Antibiotic-resistant infections kill over 35,000 people every year in the United States alone. In addition, the market expansion will be fueled by the rising prevalence of prevalence of chronic diseases. Worldwide, infectious illnesses claimed the lives of more than 17 million inhabitants.
An increase will aid the market development in the number of clinical cases where resistance to antibiotics has emerged. Antibiotic resistance market with the ability to cure serious infectious diseases is under drug trials as of June 2019, with 42 novel antibiotics in clinical trials.
Medical expenses are quite expensive. Because of the prolonged length of disease and the greater use of costly medications, the cost of medical care for people who suffer from bloodstream infections is greater than the cost of health treatment for people suffering from non-resistant illnesses.
Medical bills are high. The cost of treatment for those with infections caused is higher than for people with non-resistant diseases because the condition lasts longer and requires more expensive drugs.
Cumulative Growth Analysis
In 2017, infections caused by K. pneumoniae bacteria which are carbapenem-resistant and ESBL-producing, accounted for the majority of all infections. Because of the maximum resistance to existing treatment choices, these infections provide a significant therapeutic challenge for clinicians. Even though they are less common in terms of the number of cases compared to Gram-positive pathogens, such infectious diseases put a substantial financial burden on healthcare systems as health professionals increasingly turn to new antibiotics like Allergan's Avycaz and Melinta Therapeutics' Vabomere. On the other side, it is expected that the CDI will grow at the fastest pace throughout the predicted period.
Value Chain Analysis
According to the reports, the global antibiotic resistance market is segmented on the basis of drug class, diseases, pathogen, end-users, and regions. Cephalosporins are a kind of -lactam antibiotic resistance first acquired from the bacterium Acremonium. They are powerful against a broad spectrum of bacteria. They destroy germs and provide actions that are comparable to those of penicillin. Among the therapeutic strategies are fixed-dose mixtures of beta-lactam and beta-lactamase inhibitors, which are used to treat infections. Because of the rising usage of these medicines for gram-negative diseases that have restricted treatment alternatives, this segment accounts for the majority of the market's total revenue.
Complicated Urinary Tract Infection is the fastest-growing sector due to the fact that urinary tract infections are among the most prevalent forms of infection, with a minimum of one in every 2 women and one in every ten males experiencing a UTI at some point in their lives. UTI impacted a total of around 1,045 people.
Infections of the Skin and Skin Structure emergence of resistant pathogens are leading to a rise in hospitalizations, necessitating the development of novel alternative treatments for patients suffering from acute bacterial skin and soft tissue diseases. In 2016, the US Food and Drug Administration authorized the use of dalbavancin, tedizolid phosphate, and oritavancin for the treatment of cancer.
A considerable proportion of treatment and operations are given out in hospitals, accounting for the fastest-growing revenue growth category. Furthermore, the consumption rate of antibiotics for systemic use in clinics in 2016 was 2.1 prescribed doses per 1,000 persons per day 2016.
Antibiotic Resistance Market Segmentation Overview
The market is segmented based on drug class, diseases, pathogen, end-users, and regions. The global antibiotic resistance market trends are expected to witness decent Antibiotic Resistance Market growth during the forecast period.
Antibiotic Resistance Market, By Application
Based on the Application, the market is segmented into Complicated Urinary Tract infections, Blood Stream Infections, Complicated Intra-Abdominal Infections, Clostridium Difficile Infections, Acute Bacterial Skin and Skin Structure Infections, Hospital-Acquired Bacterial Pneumonia/Ventilator, Community-Acquired Bacterial Pneumonia, and Others.
Antibiotic Resistance Market, By end-users
Based on the propulsion types, the market is segmented into Hospitals & Clinics, Research Organizations, and Others.
Antibiotic Resistance Market Regional Analysis
According to the reports, on the basis of region, the global antibiotic resistance research market is divided into America, Europe, Asia Pacific, and the Middle East & Africa. The Americas is the most important regional market. Growing demand for prescription medicines, rising acceptance of resistance to antibiotics, and increasing frequency of infectious disorders are some of the major factors expected to propel the development of the antibiotic resistance market inside this area. Antibiotic resistance is on the increase, as is the incidence of infectious illnesses, and the number of bacterial diseases is on the upswing. Antibiotic resistance market share is expected to increase at a faster rate in Europe as a result of the variables mentioned above.
According to a recent report, due to an increase in the incidence of antibiotic-resistant diseases and hospital-acquired illnesses, Asia-Pacific is the fastest-growing leading region in antibiotic resistance. Every year, between 400,000 and 600,000 people in Germany are believed to be affected by hospital-acquired illnesses. The antibiotic resistance market in the Middle East and Africa will be driven by an increase in healthcare spending and an increase in antibiotic resistance usage.
Drug manufacturing giants are buying up smaller start-ups that are developing new antibiotics. As a result, the market's growth is projected to be shaped by this trend.
Antibiotic Resistance Market Major Key Players
The following report comprises of –
Drug Class Outlook
|Market Size||USD 17387.01 Million|
|CAGR||(5.34%) : 2020-2030|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Key Vendors||Achaogen, Inc. (US), Basilea Pharmaceutica Ltd. (Switzerland), MELINTA THERAPEUTICS, INC. (US), PARATEK therapeutics (US), Seres Therapeutics (US), Theravance Biopharma (UK), Entasis Therapeutics (US), Tetraphase Pharmaceuticals (US), Nabriva Therapeutics plc (Ireland), NEMESIS BIOSCIENCE LTD (UK), Procarta Biosystems (England),Allecra Therapeutics (US)|
|Key Market Opportunities||
|Key Market Drivers||
Antibiotic Resistance Market is expected to reach a valuation of more than USD 17387.01 million by 2030.
Antibiotic Resistance Market is expected to exhibit a strong 5.34% CAGR over the forecast period from 2020 to 2030.
Growing usage of antibiotics is the major driver for the Antibiotic Resistance Market.
The Americas are the largest regional market for antibiotic resistance.
Leading players in the Antibiotic Resistance Market include Achaogen, Seres Therapeutics, and Theravance Biopharma, among others.